Gene Biotherapeutics, Inc.
CRXMOTCHealthcare
$0.00
+$0.00(+9900.00%)
Market Cap$6493
P/E Ratio—
52W High—
52W Low—
Gene Biotherapeutics, Inc. (CRXM) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CRXM · earnings · updated Jun 10, 2026
Latest Earnings
Q4 FY2020Report Date: Dec 31, 2020EPS Actual
-$0.02
Revenue
—
Fiscal Period
Q4 FY2020
FY ends December
Report Date
Dec 31, 2020
After Market Close
CRXM reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Next earnings date not yet announced.
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2021 | Apr 23, 2021 | — | — | — | — | — | — |
| — Q4 FY2020 | Dec 31, 2020 | — | -$0.02 | — | — | — | — |
| — Q3 FY2020 | Sep 30, 2020 | — | -$0.02 | — | — | — | — |
| — Q2 FY2020 | Jun 30, 2020 | — | $0.00 | — | — | — | — |
| — Q1 FY2020 | Mar 31, 2020 | — | -$0.01 | — | — | — | — |
| — Q4 FY2019 | Dec 31, 2019 | — | $0.10 | — | — | — | — |
| — Q3 FY2019 | Sep 30, 2019 | — | -$0.01 | — | — | — | — |
| — Q2 FY2019 | Jun 30, 2019 | — | -$0.02 | — | — | — | — |
Q2 FY2021
Apr 23, 2021
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2020
Dec 31, 2020
EPS Actual
-$0.02
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2020
Sep 30, 2020
EPS Actual
-$0.02
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2020
Jun 30, 2020
EPS Actual
$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2020
Mar 31, 2020
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2019
Dec 31, 2019
EPS Actual
$0.10
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2019
Sep 30, 2019
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2019
Jun 30, 2019
EPS Actual
-$0.02
EPS Est.
—
EPS Surpr.
—
Revenue
—
No analyst estimates available for CRXM.
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q4 FY2020 | Dec 31, 2020 | — | $0.04 | $0.04 | +0.00% |
| — Q3 FY2020 | Sep 30, 2020 | — | $0.07 | $0.06 | -14.50% |
| — Q2 FY2020 | Jun 30, 2020 | — | $0.04 | $0.04 | -6.25% |
| — Q1 FY2020 | Mar 31, 2020 | — | $0.15 | $0.15 | -0.13% |
| — Q4 FY2019 | Dec 31, 2019 | — | $0.17 | $0.19 | +8.82% |
| — Q3 FY2019 | Sep 30, 2019 | — | $0.16 | $0.16 | +0.13% |
| — Q2 FY2019 | Jun 30, 2019 | — | $0.12 | $0.13 | +0.08% |
| — Q1 FY2019 | Mar 31, 2019 | — | $0.12 | $0.12 | -2.18% |
Q4 FY2020+0.00%
Report Date
Dec 31, 2020
EPS Beat/Miss
—
Price Before
$0.04
Price After
$0.04
Q3 FY2020-14.50%
Report Date
Sep 30, 2020
EPS Beat/Miss
—
Price Before
$0.07
Price After
$0.06
Q2 FY2020-6.25%
Report Date
Jun 30, 2020
EPS Beat/Miss
—
Price Before
$0.04
Price After
$0.04
Q1 FY2020-0.13%
Report Date
Mar 31, 2020
EPS Beat/Miss
—
Price Before
$0.15
Price After
$0.15
Q4 FY2019+8.82%
Report Date
Dec 31, 2019
EPS Beat/Miss
—
Price Before
$0.17
Price After
$0.19
Q3 FY2019+0.13%
Report Date
Sep 30, 2019
EPS Beat/Miss
—
Price Before
$0.16
Price After
$0.16
Q2 FY2019+0.08%
Report Date
Jun 30, 2019
EPS Beat/Miss
—
Price Before
$0.12
Price After
$0.13
Q1 FY2019-2.18%
Report Date
Mar 31, 2019
EPS Beat/Miss
—
Price Before
$0.12
Price After
$0.12
Beat Rate0 / 8 quarters
Largest Move-14.50% (Q3 FY2020)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CRXM ends December
Gene Biotherapeutics, Inc. (CRXM) most recently reported earnings on December 31, 2020 for Q4 FY2020, posting EPS of $-0.02 (in line with the analyst consensus of —).
Each quarter, investors track CRXM earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CRXM revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CRXM's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CRXM earnings · 4 questionsGene Biotherapeutics, Inc.'s next earnings report is expected around TBD. CRXM typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CRXM historically reports after market close (AMC).
CRXM earnings datewhen is CRXM earningsCRXM next earnings datewhen does CRXM report earningsCRXM earnings calendar
▸ Source: FMP · Gene Biotherapeutics, Inc. SEC filings · US GAAP · Gene Biotherapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 10, 2026